In the last years progresses have been made in the field of non small cell lung cancer (NSCLC) tumor genomic with the discovery of biomolecular markers with about 20 of patients to date treated with targeted therapies according to specific genetic alterations.
New efforts are ongoing to identify new molecular targets and new drugs. Also the field of immunotherapy have been subjected to a huge step beyond with the development of a new class of the drugs the check point inhibitors. Recently single agent immunotherapy and the combination of chemo immunotherapy are the new standard of treatments for advanced NSCLC non oncogene addicted. The new frontiers of immunotherapy are represented by the combination of new immunotherapic agents. Some of the encoureging results observed in the metastatic setting have already been traslated in earlier stages of disease.
The rationale of the meeting is to deal with and discuss all these new standard treatments and their future developments and the new paradigms of the precision medicine.